QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

The move to a deeper engagement in India is a further milestone for QIAGEN in Asia where it entered China in 2004 and Japan in 1998. Since then, the Company has expanded to more than 500 employees in Asia, with 2009 revenue in the region exceeding US$ 135 million, and believes that it has market leading positions in its focus markets. In the coming years, QIAGEN expects a growth trajectory in India similar to its successful experience in China. The New Delhi office is expected to grow to a staff of more than 30 in 2011.

QIAGEN’s diverse product portfolio is well suited to serve India’s unique healthcare needs, as well as to advance pharmaceutical R&D in India. As with other developing countries, India faces a double burden of non-communicable and communicable diseases. Demographic changes and rising living standards have also led to an increase in chronic diseases. With one of the broadest offerings in molecular diagnostics for profiling, prevention, personalized healthcare and point of need testing, as well as one of the largest sample and assay technology portfolios for drug development, QIAGEN is well positioned to serve the growing Indian market.

SOURCE QIAGEN N.V.

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s